Foghorn Therapeutics Inc (FHTX)

May 22, 2025, 7:00 AM EDT - 15 days ago

Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences

May 14, 2025, 7:00 AM EDT - 23 days ago

Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update

May 5, 2025, 7:00 AM EDT - 4 weeks ago

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference

May 1, 2025, 7:00 AM EDT - 5 weeks ago

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

Apr 28, 2025, 4:05 PM EDT - 5 weeks ago

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update

Apr 15, 2025, 7:00 AM EDT - 7 weeks ago

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting

Mar 25, 2025, 4:35 PM EDT - 2 months ago

Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting

Mar 6, 2025, 4:05 PM EST - 3 months ago

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook

Feb 25, 2025, 7:00 AM EST - 3 months ago

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

Dec 16, 2024, 7:00 AM EST - 6 months ago

Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities

Nov 12, 2024, 7:54 AM EST - 7 months ago

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

Nov 4, 2024, 4:05 PM EST - 7 months ago

Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update

Oct 10, 2024, 7:00 AM EDT - 8 months ago

Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors

Oct 1, 2024, 7:00 AM EDT - 8 months ago

Foghorn Therapeutics to Participate in the BMO Oncology Summit

Sep 3, 2024, 7:00 AM EDT - 9 months ago

Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer

Aug 28, 2024, 7:00 AM EDT - 10 months ago

Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September

Aug 8, 2024, 7:00 AM EDT - 10 months ago

Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update

May 28, 2024, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June

May 22, 2024, 6:21 PM EDT - 1 year ago

Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline

May 20, 2024, 7:58 AM EDT - 1 year ago

Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants

May 6, 2024, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

Apr 16, 2024, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer

Apr 9, 2024, 4:30 PM EDT - 1 year ago

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

Apr 5, 2024, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare Conference

Mar 26, 2024, 7:00 AM EDT - 1 year ago

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

Mar 7, 2024, 7:00 AM EST - 1 year ago

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

Mar 5, 2024, 4:48 PM EST - 1 year ago

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909

Feb 28, 2024, 7:00 AM EST - 1 year ago

Foghorn Therapeutics to Participate in Cowen's 44th Annual Health Care Conference

Dec 1, 2023, 7:00 AM EST - 1 year ago

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting

Nov 2, 2023, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update

Oct 13, 2023, 8:00 AM EDT - 1 year ago

Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress

Oct 4, 2023, 8:00 AM EDT - 1 year ago

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

Sep 11, 2023, 6:30 AM EDT - 1 year ago

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

DNLI MCRB MRNA SANA

Aug 31, 2023, 7:00 AM EDT - 1 year ago

Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML

Aug 16, 2023, 5:08 PM EDT - 1 year ago

Foghorn Therapeutics: Ifs, Buts, And Clinical Holds

Aug 4, 2023, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update

Jun 28, 2023, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma

Jun 21, 2023, 6:00 AM EDT - 2 years ago

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

DNLI MCRB MRNA SANA

Jun 7, 2023, 8:00 AM EDT - 2 years ago

Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

Jun 5, 2023, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients

May 8, 2023, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update

Apr 25, 2023, 4:05 PM EDT - 2 years ago

Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference

Apr 24, 2023, 7:20 AM EDT - 2 years ago

Foghorn Therapeutics stock slides 21% after FDA puts partial clinical hold on cancer drug trial

Apr 24, 2023, 7:00 AM EDT - 2 years ago

Foghorn Therapeutics Provides an Update on FHD-609

Apr 10, 2023, 4:05 PM EDT - 2 years ago

Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual Meetin

Apr 6, 2023, 4:05 PM EDT - 2 years ago

Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting

Mar 9, 2023, 7:00 AM EST - 2 years ago

Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update

Dec 5, 2022, 7:00 AM EST - 2 years ago

Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting

Nov 22, 2022, 8:00 AM EST - 2 years ago

Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference